# Human Immunodeficiency Virus-1 Infection:  Developing Systemic Drug Products for Pre-Exposure Prophylaxis - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/human-immunodeficiency-virus-1-infection-developing-systemic-drug-products-for-pre-exposure-prophylaxis/954b4104-b554-475b-90aa-d413f78e97c8

> FDA guidance document: Human Immunodeficiency Virus-1 Infection:  Developing Systemic Drug Products for Pre-Exposure Prophylaxis. Issue date: March 18, 2019. Get complete insights and analysis.

---

## Details

- Title: Human Immunodeficiency Virus-1 Infection:  Developing Systemic Drug Products for Pre-Exposure Prophylaxis
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2019-03-18
- Last Changed: 2019-10-29
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2018-D-1918">FDA-2018-D-1918</a>

## Related Documents

- [Smallpox (Variola Virus) Infection: Developing Drugs for Treatment or Prevention Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/smallpox-variola-virus-infection-developing-drugs-for-treatment-or-prevention-guidance-for-industry/c6eb4d8b-888a-4dc5-bb4d-877f66f968fb)
- [Anthrax: Developing Drugs for Prophylaxis of Inhalational Anthrax Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/anthrax-developing-drugs-for-prophylaxis-of-inhalational-anthrax-guidance-for-industry/42e7890d-c6f4-4da5-839f-438c6dc2dcf4)
- [Vulvovaginal Candidiasis:  Developing Drugs for Treatment](https://www.globalkeysolutions.net/guidances/guidance-document/vulvovaginal-candidiasis-developing-drugs-for-treatment/3c14a50c-15d0-4ad3-94ec-76a32afa2bdb)